Resources on COVID-19 and how BCBSND is responding to help protect all North Dakotans

Vyondys 53 (golodirsen)

Section: Injections
Effective Date: December 13, 2019


Vyondys 53TM (golodirsen) is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.


Coverage is subject to the specific terms of the member’s benefit plan.

Federal Employee Program members (FEP) should check with their Retail Pharmacy Program to determine if prior approval is required by calling the Retail Pharmacy Program at 1-800-624-5060 (TTY: 1-800-624-5077). FEP members can also obtain the list through the website.

Vyondys 53 (golodirsen) is considered experimental/investigational and therefore non-covered as there is a lack of conclusive evidence confirming clinical efficacy.

Procedure Codes

C9399   J3490

Professional Statements and Societal Positions Guidelines